Hook & thesis
LeMaitre Vascular is doing the thing compounding businesses do: steady top‑line growth, expanding margins and translating that into free cash flow. Revenue momentum (Q2 2025 revenue of $64.2M, +15% YoY), a reported gross margin near 70% and FCF of $66.226M support a premium multiple — but today’s pullback from a $115.33 52‑week high to $108.31 is a tactical entry for traders who want exposure to robust fundamentals without buying at the peak.
My trade idea: initiate a long at $108.31, limit downside with a stop at $98.00, and target $125.00 over a mid term (45 trading days) horizon. That plan captures upcoming investor visibility, potential M&A optionality funded by a $150M convertible notes program, and continued organic growth in core catheter and graft franchises. Risk is real — valuation is rich, and short interest/short volume show there are active skeptics — so the position size should reflect that.
Business snapshot - why the market should care
LeMaitre designs and sells medical devices and human tissue services focused on peripheral vascular disease. Its product set includes balloon catheters, grafts and biologic patches — devices used in a steady, aging‑driven category of medicine where recurring procedure volume and device upgrades create durable revenue streams. Management has delivered repeatable growth: Q2 2025 revenue of $64.2M grew 15% year‑over‑year and gross margins expanded to roughly 70% according to company reports, a rare margin profile in medical specialties that supports high free cash conversion.
Key fundamental and valuation facts
| Metric | Value |
|---|---|
| Current price | $108.31 |
| Market cap | $2,457,120,660 |
| Enterprise value | $2,722,100,658 |
| P/E (trailing) | ~45.1 |
| Price-to-Sales | ~10.7 |
| Free cash flow | $66.226M |
| Q2 2025 revenue | $64.2M (+15% YoY) |
| Gross margin (Q2 2025) | ~70% |
| Dividend yield | ~0.67% |
| Debt/equity | 0.44 |
| Shares outstanding | 22,686,000 |
So what does this mean? The company earns strong margins and converts a not‑insignificant portion of earnings into free cash flow. Using the current market cap of ~$2.46B, FCF of $66.226M implies an FCF yield in the low single digits (~2.7%), which helps justify valuation only if growth and margin expansion persist. The stock trades at an elevated P/S and EV/EBITDA multiples (EV/EBITDA ~37.7), so this is not a value bargain — it’s a quality‑at‑a‑price trade, betting that LeMaitre’s operating profile will continue to support premium multiple expansion.
Technicals & sentiment
Price sits above short and medium moving averages (10/20/50) and returned to a 52‑week high of $115.33 as of 02/26/2026 before an intraday pullback to $108.31 today. Momentum indicators show a bullish MACD and a high RSI (~73.9), indicating the name is extended in the very near term. Short interest is material in absolute terms (~1.17M shares, about 5.2% of shares outstanding) and days to cover has risen to ~9.3, which can amplify moves on either side.
Catalysts (what could drive the trade)
- Investor visibility in March: Management participation at multiple conferences should re‑rate sentiment if they reiterate guidance or disclose new product rollouts.
- M&A optionality: the previously announced intention to offer $150M of convertible senior notes provides dry powder for acquisitions that could extend product breadth or accelerate growth.
- Continued organic momentum: follow‑through in core catheter and graft sales after the Q2 2025 cadence (+15% YoY) would support multiple expansion.
- Margin maintenance/expansion: keeping gross margin near 70% stabilizes cash conversion and lowers the bar for earnings leverage against current valuation.
Trade plan (actionable specifics)
Direction: Long
Entry price: $108.31
Stop loss: $98.00
Target: $125.00
Horizon: mid term (45 trading days) — this horizon is intended to capture momentum from conference appearances in March and any follow‑through from quarterly commentary or acquisition news. If the company confirms continued organic growth and margin stability, the market should reward that within this window. If instead the name stalls, the stop at $98 limits capital at risk.
Rationale for levels: entry at the current price avoids averaging up and locks exposure before conference‑driven headlines; stop at $98 sits below near‑term support zones (psychological $100 and recent intraday lows) while limiting downside to a defined amount; $125 is an attainable target if positive catalysts and earnings commentary trigger multiple expansion from today’s elevated but pressurable multiples.
Risks & counterarguments
- Valuation risk: Multiples are high (P/E ~45, P/S ~10.7 and EV/EBITDA ~37.7). If revenue growth slows or margins compress, the stock can re‑rate quickly. A reversion in multiple toward more conservative medical‑device comps would create downside even with steady cash flow.
- Dilution / capital structure: The $150M convertible notes program increases dilution risk and could pressure the stock if conversion economics or new debt metrics are viewed unfavorably.
- Regulatory & reimbursement: As a device company, LeMaitre’s products depend on hospital budgets and reimbursement pathways. Changes in procedure volumes, buyer preferences or reimbursement could materially impact revenue.
- Competition & execution: Larger medical device suppliers can compete on price, distribution and installed base. Execution missteps on product launches or supply chain hiccups would hurt the story.
- Momentum & sentiment flip: Heavy short interest and elevated short volume on recent sessions mean sentiment can swing quickly; a negative headline or weaker guidance could trigger stop‑hunts and rapid downside.
Counterargument to the long thesis: The market is already pricing a high‑quality outcome. With FCF yield in the low single digits and rich multiples, any slowdown in organic growth (below the mid‑teens year‑over‑year) or a one‑time cost pressure could force a meaningful multiple contraction. In that scenario, a lower entry point would be preferable.
What would change my mind
- If management reveals meaningful execution problems (missed bookings or supply constraints) or Q‑on‑Q organic revenue turns negative, I would exit and reassess fundamentals before re‑entering.
- A material margin deterioration (gross margin moving materially below the 70% level reported) would force a downgrade of the thesis — high margins are a central pillar of the current valuation.
- If convertible note economics shift to an unexpectedly dilutive structure or management signals aggressive dilution for large non‑strategic deals, the risk/reward would change materially.
Conclusion
LeMaitre Vascular is the kind of small‑cap medical device compounder that rewards patient investors when growth and margins stick. The company’s Q2 2025 results (revenue $64.2M, +15% YoY; gross margin ~70%) and solid free cash flow underpin a premium multiple, but that premium is a two‑edged sword: it demands continued execution.
The recommended trade - long at $108.31, stop $98.00, target $125.00 over 45 trading days - is a pragmatic way to own the compounding story with defined downside. Keep position sizing mindful of valuation risk and be ready to tighten stops or trim on failure to meet conference‑driven expectations. If LeMaitre can sustain growth and margins, the market will likely re‑rate the business higher; if not, the stop protects capital and lets you reevaluate on clearer data.
Key dates to watch
- Investor conferences in March - management appearances and 1x1s (heightened visibility)
- Ex‑dividend date 03/12/2026 and payable 03/26/2026 (small yield, but an event)